Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
4(67%)
Results Posted
100%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
4
67%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(1)
Terminated(1)

Detailed Status

Recruiting2
Active, not recruiting2
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 24 (66.7%)

Trials by Status

completed117%
recruiting233%
terminated117%
active_not_recruiting233%

Recent Activity

4 active trials
Showing 5 of 6
active_not_recruitingphase_2

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

NCT04847466
completedphase_1

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

NCT04050709
recruitingphase_2

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

NCT06239220
recruitingphase_2

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

NCT06061809
active_not_recruitingphase_2

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

NCT04390399
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04847466Phase 2

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Active Not Recruiting
NCT04050709Phase 1

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Completed
NCT06239220Phase 2

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Recruiting
NCT06061809Phase 2

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Recruiting
NCT04390399Phase 2

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Active Not Recruiting
NCT04927884Phase 1

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Terminated

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6